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Abstract
Estrogen, a natural immunomodulator, regulates the development and function of diverse
immune cell types. There is now renewed attention on neutrophils and neutrophil serine pro-
teases (NSPs) such as neutrophil elastase (NE), proteinase 3 (PR3), and cathepsin G (CG)
in inflammation and autoimmunity. In this study, we found that although estrogen treatment
significantly reduced total splenocytes number, it markedly increased the splenic neutrophil
absolute numbers in estrogen-treated C57BL/6 (B6) mice when compared to placebo con-
trols. Concomitantly, the levels of NSPs and myeloperoxidase (MPO) were highly upregu-
lated in the splenocytes from estrogen-treated mice. Despite the critical role of NSPs in the
regulation of non-infectious inflammation, by employing NE-/-/PR3-/-/CG-/- triple knock out
mice, we demonstrated that the absence of NSPs affected neither estrogen’s ability to
increase splenic neutrophils nor the induction of inflammatory mediators (IFNγ, IL-1β, IL-6,
TNFα, MCP-1, and NO) from ex vivo activated splenocytes. Depletion of neutrophils in vitro
in splenocytes with anti-Ly6G antibody also had no obvious effect on NSP expression or
LPS-induced IFNγ and MCP-1. These data suggest that estrogen augments NSPs, which
appears to be independent of enhancing ex vivo inflammatory responses. Since estrogen
has been implicated in regulating several experimental autoimmune diseases, we extended
our observations in estrogen-treated B6 mice to spontaneous autoimmune-prone female
MRL-lpr, B6-lpr and NZB/WF1 mice. There was a remarkable commonality with regards to
the increase of neutrophils and concomitant increase of NSPs and MPO in the splenic cells
of different strains of autoimmune-prone mice and estrogen-treated B6 mice. Collectively,
since NSPs and neutrophils are involved in diverse pro-inflammatory activities, these data
suggest a potential pathologic implication of increased neutrophils and NSPs that merits fur-
ther investigation.
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Introduction
Estrogen has been shown to regulate the immune system of both normal and autoimmune
individuals either via activation of estrogen receptor α (ERα) and/or ERβ or through ER-inde-
pendent mechanisms [1–5]. It has been reported that in vivo estrogen exposure promotes the
production of inflammatory cytokines such as interferon-gamma (IFNγ), Interleukin (IL)-6,
IL-1β, chemokines such as monocyte chemoattractant protein (MCP)-1 and MCP-5), and
inflammatory molecules such as nitric oxide (NO) in Concanavalin A (Con A) or lipopolysac-
charide (LPS)-activated mouse splenic lymphoid cells and/or peritoneal macrophages [6–9].
Further, estrogen is capable of promoting B cell survival and activation or breakdown of B cell
tolerance to induce lupus-related serology and pathology in non-autoimmune mice [10–13].
Together, these data demonstrate a pivotal role of estrogen in the regulation of T and B lym-
phocyte-mediated inflammation and autoimmune responses. While the regulatory role of
estrogen on T and B lymphocytes is well documented, its effects on neutrophils remains largely
unknown.
Neutrophils, a major leucocyte subset of innate immune cells, are the first line of cellular
defense against invading pathogens. Neutrophils counter invading pathogens via a variety of
mechanisms that include phagocytosis, respiratory burst, and recently identified NETosis [14,
15]. Neutrophil derived serine proteases (NSPs) including neutrophil elastase (NE), proteinase
3 (PR3), and cathepsin G (CG) are essential for neutrophils scavenging of infectious agents. In
addition, NSPs play important roles in the regulation of non-infectious inflammatory
responses via proteolytic processing of cytokines, chemokines, and signaling molecules such as
NF-κB and p21 [14, 16, 17]. Furthermore, NSPs can regulate inflammation via activation of
cell surface receptors such as integrins, protease-activated receptors (PARs), and toll-like
receptors (TLRs) [14, 16–18]. In addition to their primary role in innate immune responses
and inflammation, neutrophils are also critically involved in the adaptive immune response by
attracting T cells to sites of inflammation and/or by priming and engaging T cell activation
[19, 20].
Sex differences in neutrophil counts have long been observed in men and women. Women
usually have higher neutrophil numbers than men [21], which could, in part, contribute to
stronger immune responses in women compared to men. The potential effect of estrogen on
neutrophils is suggested by the observation that the neutrophil counts in women fluctuate dur-
ing the menstrual cycle and that increased neutrophil percentages are associated with higher
serum estradiol [22–24]. To date, there is limited data with regard to estrogen effects on neu-
trophils and neutrophils-mediated onsite inflammatory responses. Previous studies in 1980s’
have documented that estrogen impaired hematopoiesis with decreased bone marrow cellular-
ity, causing lymphopenia and neutropenia in estrogen-treated mice [25, 26]. A later study
however has shown that estrogen and its metabolites were able to stimulate granulocytic differ-
entiation in myoblasts and induced neutrophilia in mice [27]. Estrogen treatment was able to
reduce the vascular injury response via inhibiting inflammatory mediator production and
then attenuating neutrophil infiltration to injured arteries [28]. However, in a different murine
influenza infection model, estrogen treatment enhanced pulmonary recruitment of neutro-
phils to potentiate virus-specific CD8+ T cells response for virus clearance [29]. This suggests
that the effect of estrogen on neutrophils depends on the experimental context and tissue type.
In this study, we investigated the estrogen effect on neutrophils in bone marrow, blood and
splenic lymphoid tissues to enable a better understanding of the potential broad tissue effects
of estrogen on neutrophils. Our study clearly shows that estrogen upregulates neutrophils in
the above lymphoid organs and promotes NSP expression in whole splenocytes. Abnormal
expression and function of NSPs has been implicated in the pathogenesis of many chronic
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autoimmune inflammatory diseases including SLE [14, 30]. Nevertheless, depletion of NSPs in
vivo in mice and depletion of neutrophils in vitro in splenocytes had no obvious effect on LPS
induced inflammatory responses in splenocytes of estrogen-treated mice. This suggests that
increased neutrophils and NSPs are not directly involved in estrogen-mediated promotion of
inflammatory responses. Since estrogen has been reported to induce lupus-related autoim-
mune inflammatory parameters[10–13], we therefore investigated whether there are also
changes of neutrophils and NSPs in the spleen of three different genetically lupus-prone
murine models (MRL-lpr, B6-lpr, and NZB/WF1), which manifest varied forms of lupus and
other systemic autoimmune diseases. The finding of a similar augmentation of neutrophils
and NSPs in the spleens of different spontaneous murine lupus models and estrogen-treated
wild-type B6 mice suggests a potential significance of estrogen upregulation of neutrophils and
NSPs in autoinflammation.
Materials and methods
Ethics statement and mice
All animal experimental procedures and housing have been approved by the Institutional Ani-
mal Care and Use Committee (IACUC) of Virginia Tech (Protocol ID# 12-131-CVM). The
experimental mice were euthanized by cervical dislocation in strict accordance with approved
IACUC protocol and regulations. To minimize suffering and to ensure a successful euthanasia
of mice within seconds, cervical dislocation was carried out only by well-trained and approved
research staff. All mice were housed in our AAALAC accredited animal facility at the Virginia-
Maryland College of Veterinary Medicine (VMCVM), Virginia Tech. Mice were fed with a
commercial 7013 NIH-31 Modified 6% Mouse/Rat Sterilizable Diet (Harlan Laboratory,
Madison, WI, USA) and given water ad libitum.
Three to four week-old male C57BL/6 (B6) mice were purchased from the Charles River
Laboratories, USA. The NE-/-/PR3-/-/CG-/- triple knock out (NECGPR3 deficient[31], referred
as NSP-/- in the text) breeders on B6 background were kindly provided by Dr. Christine T.N.
Pham from the Washington University Medical School and bred in our animal facility. Geneti-
cally autoimmune-prone female MRL/MpJ-Faslpr/J (MRL-lpr, stock No: 006825), B6.
MRL-Faslpr/J (B6-lpr, stock No: 000482), NZBWF1/J (NZB/WF1, stock No: 100008), and their
respective control female MRL/MpJ (MRL, stock No: 000486), B6, and NZW/LacJ (NZW,
stock No: 001058) mice were purchased from The Jackson Laboratory, ME, USA. These three
strains of mice spontaneously develop different manifestations of lupus and other forms of sys-
temic autoimmune diseases. The female MRL-lpr, B6-lpr, and their control female MRL and
B6 mice were euthanized at 3–4 months old; the female NZB/WF1 and its control female NZW
mice were euthanized at 7–9 months old for the experimental analysis.
For estrogen implant treatment, the 4–5 week-old male B6 and NSP-/- mice were orchidec-
tomized and implanted with 17-β estradiol (Sigma-Aldrich, Saint Louis, MO, USA) or empty
(placebo control) silastic implants following our standardized lab protocol [8, 32–34]. After
seven to eight weeks of treatment, the mice were euthanized to isolate splenocytes and/or bone
marrow cells for experimental analysis. The serum estrogen levels in estrogen-implanted mice
generated by this standard lab practice have been reported previously (ranged from 140 to 270
pg/ml at 7 wks of treatment) [8, 33].
Splenocyte preparation and culture
Mouse splenocytes were isolated using well-established lab procedures that have been
described in detail before [8, 32–34]. The splenocytes were resuspended at 5 × 106 cells/ml in
phenol red free RPMI-1640 medium (Mediatech Inc, Manassas, VA, USA) supplemented with
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10% charcoal-stripped fetal bovine serum (Atlanta Biologicals, Flowery Branch, GA, USA), 2
mM L-glutamine (HyClone Labs Inc, Logan, UT, USA), 100 IU/ml penicillin and 100 μg/ml
streptomycin (HyClone), and 1% non-essential amino acids (HyClone). The inadvertent
potential estrogenic effect of culture media was carefully avoided by the use of phenol red free
RPMI and charcoal-stripped fetal bovine serum.
To activate splenocytes, 2.5 x106 cells were seeded in 24-well plates and stimulated with 500
pg/ml of LPS (Sigma-Aldrich) as designated in the ensuing figures and figure legends. The cell
pellets were collected for Western blot analysis and the culture supernatants were collected for
analysis of cytokine and chemokine levels by the ELISA assay.
Western blotting
The whole cell extracts were prepared by lysing the cell pellet with CelLyticM Cell Lysis
Reagent (Sigma-Aldrich). Western blotting was performed per our previously published pro-
tocol to analyze the protein expression in the whole cell extracts [33, 35]. The anti-NE (N18,
sc-9518), anti-PR3 (p20, sc-19748), and anti-iNOS (M19, sc-650) antibodies were purchased
from Santa Cruz Biotechnology Inc., Paso Robles, CA, USA. The anti-CC/DPPI (AF1034-SP)
and anti-MPO (AF3667-SP) antibodies were purchased from Novus Biologicals, Littleton, CO,
USA. The protein loading control antibody, anti-β-actin antibody (ab8227), was obtained
from Abcam Inc., Cambridge, MA, USA.
Protease and elastase activity assay
The EnZCheck protease Assay (E6638) kit and EnZCheck elastase assay (E12056) kit (Invi-
trogen, Grand Island, NY, USA) were used to measure the protease and elastase activities,
respectively in whole splenocytes. Briefly, the freshly isolated splenocytes were lysed with
CelLytic™M Cell Lysis Reagent (Sigma-Aldrich). All samples were adjusted with the lysis
buffer to the same concentration, and equal amounts of protein from each sample were incu-
bated with BODIPY1 FL dye conjugated substrates (casein for protease assay and DQ™ elas-
tin for elastase assay) in 1X digestion buffer for 24 hrs. The fluorescence signal that reflects
protease activity was measured by using a Spectra Max Gemini XPS microplate reader
(Molecular Device, Sunnyvale, CA, USA) with excitation 485nm/emission 538nm. Since
DQ™ elastin can also be digested by proteases other than elastase, a selective inhibitor of elas-
tase N-methoxysuccinyl-Ala-Ala-Pro-Val-chloromethylketone (25μM-100 μM) was added
to the separate parallel assay reaction following manufacturer’s instruction to determine the
specificity of elastase activity.
Assay of serine protease activity in living splenocytes
The Fluorescent-Labeled Inhibitors of Serine Protease (FLISP)™ detection kits (Immuno-
Chemistry Technologies LLC, Bloomington, MN, USA) were utilized to measure intracellular
serine protease activity in the living splenocytes. The Carboxyfluorescein (FAM)-Spacer-Phe-
nylalanine (Phe)-Chloromethyl Ketone (CMK) FLISP assay kit (FSFCK) and FAM- Spacer-
Leucine (Leu)-CMK FLISP assay kit (FSLCK) can detect chymotrypsin-like serine proteases
that favor targeting amino acid phenylalanine and leucine, respectively. Briefly, 200 μl of sple-
nocytes at 5x106/ml were plated in U bottom 96 well culture plates and incubated with 7.5μM
of FSFCK or FSLCK reagent at 37˚C, 5% CO2 incubator for 1.5 to 2 hrs. Then, the cells were
washed three times with wash buffer, resuspended with PBS buffer containing 0.5% BSA, and
analyzed by Flow Cytometer to determine the FAM signal intensity, which reflects the serine
protease activity.
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Depletion of neutrophils in vitro from splenocytes
The EasySep™ Mouse Streptavidin RapidSpheres™ Isolation Kit (STEMCELL Technologies
Inc., Vancouver, BC, Canada) was used to deplete splenic neutrophils in vitro. Briefly, the sple-
nocytes were collected and suspended in MACS buffer (PBS containing 0.5% BSA and 2 mM
EDTA) at 1x108/ml. Normal Rat serum (50 μl/ml) was added to the cells before the addition of
specific antibody. To deplete neutrophils, biotin conjugated anti-mouse Ly6G or anti-mouse
Gr-1 antibody (Biolegend, San Diego, CA, USA) was added into a 5 ml polystyrene round-bot-
tom tube containing 1.5x107 splenocytes (150 μl) at a concentration of 2 μg/ml and then incu-
bated at RT for 10 minutes, and then incubation with streptavidin beads (25 μl/ml) at RT for
2.5 minutes. After adding 1.5 ml MACS buffer, the tube (without cap) was placed into magnet
immediately, incubated at RT for 2.5 minutes. Subsequently, the neutrophil-depleted spleno-
cytes were collected in a new collection tube, pelleted, and resuspended in complete RPMI
medium at 5x106/ml for cell culture. Aliquot of splenocytes that was incubated with streptavi-
din beads only was served as control (No-Ab control).
Real-time RT-PCR
Total RNA was isolated from freshly prepared splenocytes and purified splenic cells subsets
using RNAeasy mini kit (Qiagen, Valencia, CA, USA) or mirVana miRNA isolation kits
(Ambion). Any contaminated residual DNA was removed either by performing on-column
DNase digestion during RNA isolation (RNAeasy mini kit) or by using RQ1 RNase-free DNA-
ase (Promega, Madison, WI, USA) after RNA is extracted (mirVana miRNA isolation kit) per
the manufacturer’s instruction. The iScript one-step RT-PCR with SYBR green kit (Bio-Rad,
Hercules, CA, USA) was used for quantifying gene expression. Quantitect 10 × PCR primer
mixes for mouse NE, PR3, CG, myeloperoxidase (MPO), and β-actin were purchased from
Qiagen. The relative NSP mRNA expression levels were normalized to β-actin levels and calcu-
lated using the 2−ΔΔCt (Livak) method.
Detection of inflammatory molecules in culture supernatant
As reported previously [33–35], the level of the NO indicator, nitrite in cell culture supernatant
was measured by the Griess assay. The levels of Th1 cytokines IFNγ, IL-1β, IL-6, TNFα, and
Th2 cytokine IL-10 were measured by Ciraplex multiplex Chemiluminescent Assay kit
(Aushon Biosystem Inc., Billerica, MA, USA). The chemokine MCP-1 level was measured
with mouse MCP-1 ELISA MAX™ Deluxe kit (Biolegend Inc., San Diego, CA, USA).
Statistical analysis
All values were reported as mean ± SEM. Two tailed, unpaired t tests were performed to assess
statistical significance of mRNA expression levels, protease activities between two biological
groups (placebo vs estrogen; MRL vs MRL-lpr; B6 vs B6-lpr; NZW vs NZB/WF1). Paired t tests
were performed to assess the statistical significance between control and specific treated sam-
ples (without inhibitor vs with inhibitor; No-Ab control vs anti-Ly6G or anti-Gr-1).
Results
Increased protease and elastase activity in splenocytes from estrogen-
treated B6 mice
We have previously reported a serine protease mediated truncation of STAT-1 and NF-κBp65
proteins in the nuclear extracts of splenocytes from estrogen-treated B6 mice [35], which
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suggested a potential regulatory effect of estrogen on serine proteases. We therefore measured
the total protease activity in whole cell lysates of freshly isolated splenocytes from placebo- and
estrogen-treated mice. As expected, the protease activity was significantly increased in spleno-
cyte lysates from estrogen-treated B6 mice compared to placebo controls (Fig 1A). By using
FLISP Serine Protease Detection Assay, we further demonstrated that there was a significantly
higher chymotrypsin-like serine protease activity in living splenocytes from estrogen-treated
mice when compared to placebo controls (Fig 1B). We then measured the specific elastase
activity in splenocytes using a commercially available EnZCheck elastase assay kit. As shown
in Fig 1C, the protease activity was significantly increased in splenocytes from estrogen-treated
mice (without inhibitor: placebo vs estrogen). The addition of a selective elastase inhibitor, N-
methoxysuccinyl-Ala-Ala-Pro-Val-chloromethylketone (100 μM) significantly reduced the
protease activity (estrogen: without inhibitor vs with inhibitor), suggesting a major
Fig 1. The protease and elastase activities are increased in splenocytes from estrogen-treated mice
when compared to placebo controls. (A) The total protease activity in freshly isolated splenocytes from
placebo- and estrogen-treated B6 mice was determined by EnzChek Protease Assay kit. The graph shows the
mean ± SEM (n7). (B) The chymotrypsin-like serine protease activity in whole living splenocytes was detected
with FLISP™ serine protease detection kit. Freshly isolated splenocytes were stained with FSFCK (upper left
panel) or FSLCK (upper right panel) FLISP reagent, which detected chymotrypsin-like serine proteases favoring
phenylalanine and leucine, respectively. The FAM signal intensity in living splenocytes (gated on propidium
iodide (PI) negative cells) was analyzed by flow cytometry. The representative flow scatter plots are shown. The
table in the lower panel shows the FAM value (mean ± SEM) summarized from the Flow data (n6). (C) The
elastase activity in freshly isolated splenocytes from placebo- and estrogen-treated B6 mice was determined by
EnZCheck elastase assay kit with or without the addition of inhibitor in the reaction. Mean activity ± SEM (n4)
is shown. (D) The graph demonstrates that the activity of purified porcine pancreatic elastase was completely
blocked by a selective inhibitor, N-methoxysuccinyl-Ala-Ala-Pro-Val-chloromethylketone at 100 μM
concentration. Either unpaired student t test (placebo vs estrogen) or paired student t test (without inhibitor vs
with inhibitor) were performed; *, p<0.05, ** p<0.01, and ***, p <0.001.
doi:10.1371/journal.pone.0172105.g001
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contribution of elastase to the increased protease activity observed in splenocytes from estro-
gen-treated mice (Fig 1C). While the selective elastase inhibitor at 100 μM completely blocked
the activity of the positive control (purified porcine pancreatic elastase, Fig 1D), it only par-
tially inhibited the protease activity in splenocytes from estrogen-treated mice (Fig 1C). This
suggests that in addition to elastase, estrogen also upregulated other types of proteases/serine
proteases.
Enhanced neutrophil serine protease expression in splenocytes from
estrogen-treated B6 mice
While there are a variety of serine proteases produced in different immune cell types, NSPs are
of particular interest because of their role in the regulation of non-infectious inflammation
[17]. With the finding of increased elastase activity in estrogen-treated splenocytes, we next
examined whether estrogen treatment affects the expression of NE or other NSPs in spleno-
cytes. Real-time RT-PCR analysis indicated that mRNA expression levels of all three NSPs
(NE, PR3, and CG) were substantially increased in the freshly isolated splenocytes from estro-
gen-treated mice when compared to placebo controls (Fig 2A). Estrogen treatment led to an
over 10-fold increase in NE mRNA level and an over 80-fold increase in PR3 and CG mRNA
levels in splenocytes. In accordance with increased mRNA levels, the protein expression of
NSPs such as NE and PR3 were also significantly enhanced in splenocytes from estrogen-
treated B6 mice when compared to placebo controls (Fig 2B). We were unable to analyze CG
protein level in these samples because the CG antibody does not work well with our western
blotting system. Cathepsin C (CC, also called Dipeptidyl peptidase I (DPPI)) is required for the
full activation of neutrophil derived NE, PR3, and CG [36]. Western blotting revealed similar
expression levels of CC/DPPI in the splenocytes of placebo and estrogen-treated mice (Fig 2C).
In vivo estrogen exposure increases the percentage of neutrophils in
spleen, blood, and bone marrow
We next determined whether estrogen alters the percentage of neutrophils in various lym-
phoid tissues. The flow cytometric analysis revealed that the percentage of mature neutrophils
(Gr-1highCD11b+) was significantly increased in splenocytes (Fig 3A), peripheral blood (Fig
3B), and bone marrow (Fig 3C) cells from estrogen-treated mice when compared to placebo-
treated mice. Consistent with our long-term observation that estrogen decreases spleen cellu-
larity, there was a significant decrease of total splenocytes counts (Fig 3D). However, there was
still a significant increase in absolute neutrophil number in the spleen (Fig 3E). Myeloperoxi-
dase (MPO), a major component of azurophilic granules, is most abundantly expressed in neu-
trophil granulocytes. Accompanying the increased neutrophil counts in the spleen, there was
also a substantial upregulation of MPO mRNA (Fig 3F) and protein (Fig 3G) levels in the sple-
nocytes from estrogen-treated B6 mice.
Estrogen-mediated promotion of inflammatory molecules and
neutrophils occurs despite the depletion of NSPs
NSPs have been shown to play an important role in the regulation of inflammatory responses,
especially at the site of inflammation [14, 16, 36]. To understand whether increased NSPs con-
tribute to estrogen-mediated promotion of inflammation in splenocytes, we utilized triple NSP
knockout (NSP-/-) mice and subjected these mice to estrogen treatment. As indicated in Fig
4A, NE and PR3 proteins were not detectable in the splenocytes of NSP-/- mice (in both pla-
cebo and estrogen treated mice). Similar to that observed in wild type B6 mice, MPO was also
Estrogen regulation of neutrophil serine proteases
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increased in splenocytes from estrogen-treated NSP-/- when compared to placebo-treated
NSP-/- mice. CC/DPPI expression level in wild type mice was similar to that in NSP-/- mice,
either with or without estrogen treatment (Fig 4A). By using the EnZCheck elastase assay kit,
we demonstrated that depletion of NSPs abolished the increase of protease activity in estro-
gen-treated B6 mice (Fig 4B). This data further suggests that the upregulation of NSPs directly
contributed to the observed increase in protease activity in splenocytes from estrogen-treated
B6 mice.
We initially hypothesized that depletion of NSPs would impede the effect of estrogen on
inflammatory mediators in ex vivo-activated splenocytes. Nevertheless, similar to estrogen-
treated wild type B6 mice, in LPS-activated splenocytes from estrogen-treated NSP-/- triple
knock out mice there was enhanced production of inflammatory mediators that include IFNγ
Fig 2. NSP expression levels are upregulated in the splenocytes from estrogen-treated B6 mice when
compared to placebo controls. (A) Real-time RT-PCR analysis of the relative mRNA expression levels of
NE, PR3, and CG in the splenocytes from placebo- and estrogen-treated B6 mice. The graph represents the
means ± SEMs (n 4). Student t tests (placebo vs estrogen) were preformed; *, p < 0.05; **, p < 0.01; and
***, p < 0.001. (B and C) Western blot analysis of NE and PR3 (B), CC/DPPI (C) protein expression levels in
the whole splenocyte extracts from placebo- and estrogen-treated mice. β-actin was probed as a protein
loading control.
doi:10.1371/journal.pone.0172105.g002
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Fig 3. Estrogen treatment increases neutrophil percentages in wild type B6 mice. (A-C) Flow cytometry analysis.
Red blood cell-depleted whole splenocytes (A), peripheral blood (B), and bone marrow (C) cells from placebo- and
estrogen-treated mice were stained with neutrophil surface markers FITC conjugated anti-Gr1 and APC conjugated anti-
CD11b antibodies. Shown are the representative FACS plots from at least three independent experiments accompanied
by the summary graphs showing the percentages (means ± SEMs) of neutrophils in the spleen, blood, and bone marrow
cells from placebo- and estrogen-treated mice (n4). (D) The total splenocyte count in placebo- and estrogen-treated
mice. (E) The total CD11b+GR1+ splenic neutrophil count in placebo- and estrogen-treated mice. (F) Real-time RT-PCR
analysis of the expression of MPO in splenocytes from placebo- and estrogen-treated mice. The graphs show
means ± SEMs (n4). Unpaired student t tests (placebo vs estrogen) were performed. *, p < 0.05; **, p < 0.01; and ***,
p < 0.001. (G) Western blot analysis of MPO protein expression levels in the splenocytes from placebo- and estrogen-
treated mice. β-actin was probed as protein loading control.
doi:10.1371/journal.pone.0172105.g003
Estrogen regulation of neutrophil serine proteases
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(Fig 5A), IL-1β (Fig 5B), IL-6 (Fig 5C), IL-10 (Fig 5D), TNFα (Fig 5E), MCP-1 (Fig 5F), NO
(Fig 5G), and iNOS (Fig 5H) when compared to placebo-treated NSP-/- mice.
In the absence of NSPs, estrogen was still capable of increasing neutrophil percentages in
the spleen and bone marrow. Akin to estrogen-treated wild type B6 mice (Fig 3A and 3C),
there was also a significant upregulation of Gr-1highCD11b+ neutrophils in the spleen and
bone marrow of estrogen-treated NSP-/- knock out mice when compared to placebo-treated
NSP-/- mice (Fig 6A and 6C). The increase of neutrophils in blood was however not significant
in estrogen-treated NSP-/- mice (p = 0.07, Fig 6B). Consistent with increased neutrophils, the
expression of MPO was also increased in estrogen-treated NSP-/- mice when compared with
Fig 4. Depletion of NSPs abrogated estrogen-mediated promotion of protease activity in splenocytes.
(A) Western blot analysis of NE, PR3, MPO, and CC/DPPI proteins in the splenocytes of placebo and
estrogen-treated wild type (WT) and NSP-/- knock out B6 mice. β-actin was probed as protein loading control.
(B) Analysis of protease and elastase activity in splenocytes from placebo- and estrogen-treated WT and
NSP-/- mice with EnZCheck elastase assay kit. The graph shows the mean ± SEM (n4). Unpaired student t
tests (placebo vs estrogen) and paired student t test (WT/estrogen; without inhibitor vs with inhibitor) were
preformed; ***, p < 0.001; and ns, not significant.
doi:10.1371/journal.pone.0172105.g004
Estrogen regulation of neutrophil serine proteases
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placebo-treated NSP-/- mice (Fig 4A). These data suggest that the effects of estrogen on above
inflammatory molecules and neutrophils appear to be independent of estrogen-mediated pro-
motion of NSPs.
Depletion of splenic neutrophils in vitro has limited effect on splenic cell
immune responses
The above data indicates that depletion of NSPs has no obvious effect on estrogen-mediated
induction of inflammatory cytokines. To further understand the potential biological implica-
tion of increased neutrophils in estrogen-treated mice, we depleted splenic neutrophils in vitro
with either anti-mouse Ly6G (specific for neutrophils) or anti-mouse Gr-1 (neutrophils and
monocytes) antibody. As indicated, both anti-mouse Ly6G and Gr-1 efficiently depleted
CD11b+Ly6G+ neutrophils (Fig 7A) from splenocytes, but had no effect on CD4+ T (Fig 7B),
and CD19+ B lymphocytes (Fig 7C). To our surprise, we found that depletion of
CD11b+Ly6G+ neutrophils did not significantly reduce NSP or MPO mRNA expression in the
splenocytes (Fig 7D). Also, specific depletion of Ly6G+ cells did not reduce LPS-induced IFNγ,
IL-6 and MCP-1 (Fig 7E–7G). Indeed, there was a slight, but significant increase of IL-6 in
either anti-Ly6G or anti-Gr-1 depleted splenocytes (Fig 7F). However, depletion of Gr-1+ cells
with anti-Gr-1 antibody suppressed LPS-induced IFNγ in placebo-treated splenocytes and
MCP-1 in estrogen-treated splenocytes (Fig 7E and 7G), suggesting a potential involvement of
Gr-1+ monocytes in LPS-induced IFNγ and MCP-1 in splenocytes. Together, our data suggests
Fig 5. Depletion of NSPs has no obvious effect on estrogen-mediated promotion of inflammatory molecules and
neutrophils. The splenocytes from placebo- and estrogen-treated wild type (WT) and NSP-/- knock out mice were
stimulated with LPS for the indicated times. The culture supernatant was collected to measure cytokines IFNγ (A), IL-1β
(B), IL-6 (C), IL-10 (D), TNFα (E), chemokine MCP-1 (F), and inflammatory molecule NO (G). The expression level of iNOS
protein in LPS activated splenocytes (24hr) was measured by Western blotting (H). The graphs show means ± SEMs
(n = 3 for wild type B6 mice and n = 5 for NSP-/- mice). Unpaired student t test (placebo vs estrogen); *, p < 0.05; **,
p < 0.01; and ***, p < 0.001.
doi:10.1371/journal.pone.0172105.g005
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that neutrophils have limited effect on LPS-induced inflammatory molecules in splenocytes
from placebo- and estrogen-treated mice.
Increased neutrophils and NSP expression in the spleen cells of different
spontaneous murine lupus models
Since estrogen is known to regulate autoimmune diseases, we extended our studies to deter-
mine whether similar changes to neutrophil numbers and NSPs are also evident in several
strains of autoimmune-prone mice. Analogous to our observation in the estrogen-induced
murine inflammation model, there was a significant increase in neutrophil percentage in the
spleens of autoimmune-prone female MRL-lpr (Fig 8A), B6-lpr (Fig 8B), and NZB/WF1
Fig 6. Estrogen treatment increases neutrophil percentages in NSP-/- knock out mice. Red blood cell-
depleted whole splenocytes (A), peripheral blood (B), and bone marrow (C) cells from placebo- and estrogen-
treated NSP-/- knockout mice were stained with neutrophil surface markers as described in Fig 3. The
representative FACS plots are shown. The summary graphs show the percentages of neutrophils
(CD11b+GR1+) in the spleen, blood, and bone marrow cells from placebo- and estrogen-treated NSP-/- mice
(means ± SEMs, n5). Unpaired student t test (placebo vs estrogen) were preformed; ***, p < 0.001.
doi:10.1371/journal.pone.0172105.g006
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(Fig 8C) when compared to their respective control female MRL, B6, and NZW mice. How-
ever, unlike estrogen-treated B6 mice, there was no increase of neutrophils in the blood and
bone marrow of above three strains of autoimmune-prone mice (data not shown). Consistent
with increased neutrophil percentage, there were also increased NSP and MPO mRNA expres-
sion levels in the splenocytes from MRL-lpr (Fig 8D), B6-lpr (Fig 8E) and NZB/WF1 (Fig 8F)
when compared to their respective controls. Western blot analysis indicated that NE, PR3 and
MPO protein expression levels were also significantly increased in splenocytes from MRL-lpr
and B6-lpr mice when compared to their respective controls (Fig 8G). While NE and PR3 pro-
teins were increased in NZB/WF1 mice (compared to control NZW mice), their expression lev-
els were still very low. Since MPO protein was already expressed at relatively high levels in the
NZW control, the increase of MPO protein levels in NZB/WF1 was not as prominent as that in
lpr lupus mice (Fig 8G). Together, our data indicates an increase of neutrophil percentage and
NSP expression in the spleens of different spontaneous lupus strains.
Discussion
There is now a wealth of data indicating that estrogen regulates the development and functions
of T cell subsets (Th1, Th2, Treg) and B cell subsets (B1 and B2) [1, 11, 13, 37, 38]. Estrogen is
also known to regulate the development, differentiation and functions of dendritic cells, mac-
rophages and monocytes [1, 39]. However, the data with regards to the regulatory effect of
estrogen on neutrophils are limited.
Neutrophils have a short life span and therefore are constantly replenished from bone
marrow. The sex differences in neutrophil numbers suggest a potential regulatory role of sex
hormones such as estrogen. Studies in humans have shown neutrophilia in pregnant women
correlated with increased levels of progesterone and estrogen throughout pregnancy[23, 40].
Moreover, increased neutrophil numbers were also seen in cancer patients who received
estramustine phosphate chemotherapy treatment, which elevates serum 17-β estradiol level
Fig 7. Depletion of neutrophils in vitro from splenocytes has limited effect on LPS-induced inflammatory responses in
splenocytes. The splenocytes from placebo-and estrogen-treated mice were treated with anti-mouse Ly6G, or anti-mouse Gr-1 antibody
and magnetic beads to deplete neutrophils. The No Ab control received no any specific antibody treatment. (A-C) The graphs summarize the
flow cytometric analysis data of the percentage of CD11b+Ly6G+, CD4+ and CD19+ cells in the splenocytes after neutrophil depletion. (D)
Real-time RT-PCR analysis of the relative mRNA expression levels of NE, PR3, and CG in the splenocytes from estrogen-treated B6 mice
after neutrophil depletion. The graph represents the means ± SEMs (n = 2). (E-G) The neutrophil-depleted splenocytes from placebo- and
estrogen-treated B6 mice were stimulated with LPS for 24h, and then supernatant were collected to analyze the production of IFNγ, IL-6,
and MCP-1 by ELISA. The graphs (A-C and E-G) show means ± SEM (n = 2 for placebo with anti-Gr-1 treatment; n4 for the other
treatment groups). Paired student t test (No Ab control vs anti-Ly6G or anti-Gr-1); *, p < 0.05; **, p <0.01; and ***, p < 0.001.
doi:10.1371/journal.pone.0172105.g007
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[41]. Nevertheless, in one older murine study, estrogen appeared to have suppressive effects
on hematopoiesis and granulopoiesis, since administration of estrogen blocked the increase
of circulating lymphocytes, neutrophils, and monocytes in ovariectomized mice [42].
Together, these data suggest a regulatory effect of estrogen on neutrophils. Here, we report
an increase in neutrophil percentages in the primary lymphoid organ bone marrow, periph-
eral blood and in the secondary lymphoid organ spleen in in vivo estrogen-treated B6 mice
(Fig 3). Despite a reduction of total splenic cellularity, the absolute splenic neutrophil counts
were increased (Fig 3E), in addition to increased percentage (Fig 3A). Since 7–8 wks of estro-
gen implant treatment in mice causes osteopetrosis and diminishes the bone marrow cavity,
Fig 8. Neutrophil percentages are increased in the splenocytes of three different strains of spontaneous
lupus-prone mice. (A-C) The flow cytometric analysis of neutrophils (CD11b+GR1+) in the splenocytes from
MRL-lpr (A), B6-lpr(B), NZB/WF1 (C) lupus mice and their respective control MRL, B6, and NZW mice.
Representative FACS plots are shown. The graphs show the summary of flow analysis of neutrophil percentage
in splenocytes of different strains of lupus mice (means ± SEMs, n4). (D-F) Real-time RT-PCR analysis of the
relative expression levels of NE, PR3, CG, and MPO in the splenocytes from MRL-lpr (D), B6-lpr (E), NZB/WF1
(F) lupus mice and their respective control MRL, B6, and NZW mice. The graphs show means ± SEM (n4).
Unpaired student t test (MRL vs MRL-lpr; and B6 vs B6-lpr, NZW vs NZB/WF1); *, p < 0.05; **, p < 0.01; and
***, p < 0.001. (G) Western blot analysis of NE, PR3, and MPO protein expression in splenocytes from MRL-lpr,
B6-lpr, NZBWF1, and their respective control MRL, B6, and NZW. β-actin was probed as protein loading control.
doi:10.1371/journal.pone.0172105.g008
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we were unable to recover all the bone marrow cells from estrogen-treated mice to ascertain
the absolute number of bone marrow neutrophils. The precise reasons for estrogen-mediated
increase in splenic neutrophils remains unclear. It is plausible that estrogen treatment stimu-
lates splenic lymphoid cells to secrete neutrophil attracting chemokines or promotes local-
ized development and/or survival of neutrophils. This hypothesis is supported by the reports
that estrogen promotes the production of neutrophil-attracting chemokine MCP-1 in sple-
nocytes [8] and that estrogen delays spontaneous neutrophil apoptosis to induce neutrophi-
lia in pregnant women [40]. Further, although the mice appeared healthy after estrogen
treatment, we cannot rule out the possibility that estrogen may causes an undetermined
endogenous infection that enhanced neutrophil numbers and activities. We have initially uti-
lized anti-CD11b and anti-GR-1 antibodies to identify neutrophils in this study. Since Gr-1
also labels Ly6C on eosinophils and monocytes, we later used anti-CD11b and a specific
anti-Ly6G antibody to confirm the increase of neutrophils (CD11b+Ly6G+) in the spleens of
estrogen-treated B6 mice (S1 Fig).
In agreement with the increase in neutrophil counts in splenocytes of estrogen-treated
mice, we observed an increase in NSPs and neutrophil specific MPO expression (Figs 2 and 3).
The increase in NSP expression is not simply due to increased neutrophil counts in the spleen
since depletion of neutrophils in vitro from splenocytes did not reduce NSP expression levels.
We also analyzed NSP expression in both purified CD11b+ myeloid cells and CD90.2+ T cells
from placebo- and estrogen-treated B6 mice. We found that estrogen-treatment increased
NSPs and MPO mRNA expression not only in CD11b+ myeloid cells, but also in CD90.2+ T
cells (S2A–S2D Fig). The increase of NE and MPO mRNA expression was also observed in
purified splenic CD4+ T and CD19+ B cells from MRL-lpr mice when compared to that from
control MRL mice (S2E and S2F Fig). Further investigation is necessary to determine the func-
tionality of the NSPs in T cells.
Both estrogen receptor (ER)α and ERβ are expressed in neutrophils and regulate neutrophil
functions [23]. It has been reported that ERα plays an essential role in estrogen-mediated regu-
lation of inflammatory responses in different immune cell types [9, 43]. Due to an unexpected
loss of ERα-/- mice during the estrogen treatment, we can only draw limited conclusions from
the reduced number of surviving estrogen-treated ERα-/- knock out mice study. Consistent
with previous reports, our limited data indicate that depletion of ERα abolished the positive
effect of estrogen on the induction of inflammatory molecules such as NO (S3A Fig), iNOS
(S3B Fig), and MCP-1 (S3C Fig) in activated splenocytes. Moreover, depletion of ERα elimi-
nated estrogen-mediated upregulation of NSPs in the spleen (S3D Fig). This data is suggestive
of the involvement of ERα in estrogen-mediated promotion of inflammation and NSPs in sple-
nocytes, with the caveat that the limited number of estrogen-treated ERα-/- mice preclude
drawing firm conclusions.
Previous studies have shown that the absence of NSPs led to defective onsite cytokine pro-
duction in vivo in various models of inflammation [36, 44]. However, NSP deficient neutro-
phils showed no defect in cytokine/chemokine production when directly stimulated in vitro
with PMA or LPS [45]. Similarly, we noted that there were no differences in the production
of inflammatory mediators (IFNγ, IL-1β, IL-6, TNFα, MCP-1 and iNOS/NO) between LPS-
activated wild type B6 and NSP-/- splenocytes (Fig 5). Estrogen treatment promoted inflam-
matory responses in activated NSP-/- splenocytes similar to that noted in wild type B6 mice
splenocytes (Fig 5). These data suggest that the ex vivo promotion of aforementioned inflam-
matory molecules by estrogen in splenocytes might be mediated through NSP-independent
mechanisms.
Depletion of neutrophils specifically with anti-mouse Ly6G antibody in vitro from spleno-
cytes did not have an obvious effect on LPS-induced immune responses in splenocytes, while
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depletion of both neutrophils and Gr-1+ monocytes with anti-mouse Gr-1 antibody had a sup-
pressive effect on LPS-induced IFNγ and MCP-1. Remarkably, depletion of neutrophils also
did not affect the expression of NSP mRNAs suggesting that other cells may contribute to NSP
synthesis. In support of this view, we noticed that estrogen promoted NSPs in T lymphocytes
(S2 Fig).
Although the direct functional relevance of increased neutrophil counts and NSP expres-
sion in splenic cells in estrogen-mediated promotion of inflammation remains unknown, the
similar upregulation of splenic neutrophils and NSPs in estrogen-treated B6 mice and in spon-
taneous autoimmune-prone murine models implicates a potential significance of neutrophils
in estrogen mediated autoinflammatory responses. Together, our studies provide new infor-
mation about the role of estrogen in neutrophils and NSPs, which bear remarkable similarity
to that noticed in several autoimmune prone female mice. The precise contribution of altered
neutrophils and NSPs to the activity of other defined splenic cell subsets warrants further
investigation in future studies, which shall provide new perspective for understanding the cel-
lular mechanism of estrogen regulation of inflammation and autoimmunity.
Supporting information
S1 Fig. Increase of CD11b+Ly6G+ neutrophils in estrogen-treated wild type B6 mice. Red
blood cell-depleted whole splenocytes placebo-and estrogen-treated mice were stained with
neutrophil surface markers PE conjugated anti-Ly6G and PerCP-Cy5.5 conjugated anti-
CD11b antibodies. The representative flow cytometry plots are shown. The bar graph shows
the mean ± SEMs percentages of CD11b+Ly6G+ neutrophils in the splenocytes from placebo-
and estrogen-treated mice (n4).
(TIF)
S2 Fig. NSPs and MPO mRNA expression levels are increased in lymphocytes from estro-
gen-treated B6 mice and MRL-lpr mice. Splenic CD11b+ myeloid lineage cells, CD90.2+ T,
CD4+ T and CD19+ B cells were purified by positive selection, per manufacturer’s instruction,
using mouse CD11b and CD90.2 (Thy1.2), CD4 (L3T4), and CD19 microbeads (Miltenyi Bio-
tec, San Diego, CA, USA), (A-D). Real-time RT-PCR analysis of the relative mRNA expression
levels of NE (A), PR3 (B), CG (C), and MPO (D) in purified splenic CD11b+ and CD90.2+ cells
from placebo- and estrogen-treated B6 mice. The graphs represent means ± SEMs (n = 4
each). (E and F) Real-time RT-PCR analysis of the relative mRNA expression levels of NE (E)
and MPO (F) in purified splenic CD4+ T and CD19+ B cells from MRL-lpr and control MRL
mice. The graphs represent means ± SEMs (n = 2 each).
(TIF)
S3 Fig. Depletion of ERα abolished the promotion effect of estrogen on inflammatory
responses and NSPs. The 4–5 wks old, male ER knock out mice (ER-/-, purchased from the
Jackson laboratory, USA) were orchidectomized and implanted with empty (placebo control)
or 17-β estradiol silastic implants as we described for wild type B6 mice in the material and
method section. The splenocytes from placebo- and estrogen-treated wild type (WT) and
ERα-/- knock out mice were stimulated with Con A or LPS for either 24hrs or 48hrs to measure
the production of inflammatory molecules such as NO (A) and MCP-1 (C) in culture superna-
tant. Western blotting was performed to detect iNOS protein expression in Con A activated
splenocytes (24hr) (B). (D) Real-time RT-PCR analysis of NSP expression in freshly isolated
splenocytes. The graph shows means ± SEM (n = 1 for estrogen-treated ERα-/-; n = 2 for the
other treatment groups).
(TIF)
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